Tuesday, April 26, 2016
PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that it sold its U. S. prenatal screening laboratory services business PerkinElmer Labs/NTD ("NTD") to Eurofins Scientific.
"Recent changes to U.S. healthcare reform continue to drive the consolidation of diagnostics testing towards broader service providers," said Prahlad Singh, President, Diagnostics, PerkinElmer. "Eurofins, with its breadth of testing services and capabilities, is uniquely positioned to meet the expanding service needs of NTD's customers. Furthermore, the divestiture of the NTD business allows PerkinElmer to concentrate its efforts on developing innovative maternal fetal health technologies and solutions for the U.S. Outside the U.S., we will continue to provide kits, technologies and services through a variety of channels focused on improving health outcomes for babies and expectant mothers."
PerkinElmer offers a comprehensive portfolio of diagnostic solutions including: prenatal, neonatal and infectious disease screening, along with molecular diagnostics, through its wide range of instruments, reagents and assay platforms, and software offerings. PerkinElmer also provides private cord blood and cord tissue preservation to families through ViaCord LLC.
NTD generated approximately $20 million in revenue in 2015. The financial impact of the divestiture, excluding any potential gain on the sale, is not expected to have a material impact on PerkinElmer's 2016 earnings per share guidance which was provided on February 4th of this year.
Source : ir.perkinelmer.com
